230 related articles for article (PubMed ID: 33979560)
21. Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution.
Logothetis CN; Patel A; Eatrides J; Jaglal M; Haider M; Visweshwar N; Laber DA
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362201
[TBL] [Abstract][Full Text] [Related]
22. Successful Treatment of Acquired Thrombotic Thrombocytopenic Purpura With Caplacizumab Combined With Plasma Exchanges and Immune Suppression in 3 Children.
Kalinina II; Antonova KS; Avdonin PV; Klebanova EE; Kotskaya NN; Kurnikova EE; Shutova AD; Matveev VE; Maschan AA
J Pediatr Hematol Oncol; 2024 Apr; 46(3):e220-e222. PubMed ID: 38447071
[TBL] [Abstract][Full Text] [Related]
23. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab.
Chung C
Ann Pharmacother; 2021 Mar; 55(3):330-343. PubMed ID: 32715723
[TBL] [Abstract][Full Text] [Related]
24. Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: A single-center with homogeneous treatment experience.
Jiménez M; Bobillo S; Pons V; Sánchez C; Pérez A; Molero A; Miranda N; Sánchez Á; Tabares E; Bosch F; Valcárcel D
Transfusion; 2022 Nov; 62(11):2363-2369. PubMed ID: 36151933
[TBL] [Abstract][Full Text] [Related]
25. Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis.
Loscocco GG; Malandrino D; Vannini F; Vinci MC; Di Marzio G; Fallai L; Scappini B
Transfus Apher Sci; 2021 Feb; 60(1):103010. PubMed ID: 33223471
[TBL] [Abstract][Full Text] [Related]
26. Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?
Elverdi T; Özer Çerme MD; Aydın T; Eşkazan AE
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1183-1188. PubMed ID: 34130583
[No Abstract] [Full Text] [Related]
27. Five years of caplacizumab - lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura.
Völker LA; Brinkkoetter PT; Cataland SR; Masias C
J Thromb Haemost; 2023 Oct; 21(10):2718-2725. PubMed ID: 37562668
[TBL] [Abstract][Full Text] [Related]
28. Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura.
Perrone S; Passucci M; Ortu La Barbera E; Capriata M; Ferretti A; Mecozzi A; Giovangrossi P; Equitani F; Cimino G
J Clin Apher; 2021 Jun; 36(3):499-504. PubMed ID: 33459440
[TBL] [Abstract][Full Text] [Related]
29. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
Hollifield AL; Arnall JR; Moore DC
Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
He J; Qi J; Han H; Xu X; Li X; Song X; Han Y
Expert Rev Hematol; 2023 May; 16(5):377-385. PubMed ID: 37045600
[TBL] [Abstract][Full Text] [Related]
31. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.
Kühne L; Kaufeld J; Völker LA; Wendt R; Schönermarck U; Hägele H; Osterholt T; Eichenauer DA; Bieringer M; von Bergwelt-Baildon A; Fischereder M; Buxhofer-Ausch V; Menne J; Brinkkoetter PT; Knöbl P
J Thromb Haemost; 2022 Apr; 20(4):951-960. PubMed ID: 35000278
[TBL] [Abstract][Full Text] [Related]
32. Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI).
Cid J; Pérez-Valencia AI; Torrente MÁ; Ávarez-Larrán A; Díaz-Ricart M; Esteve J; Lozano M
Transfus Apher Sci; 2021 Feb; 60(1):103011. PubMed ID: 33221124
[TBL] [Abstract][Full Text] [Related]
33. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.
Peyvandi F; Cataland S; Scully M; Coppo P; Knoebl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Minkue Mi Edou J; De Winter H; Callewaert F
Blood Adv; 2021 Apr; 5(8):2137-2141. PubMed ID: 33881463
[TBL] [Abstract][Full Text] [Related]
34. Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective.
Pollissard L; Leinwand BI; Fournier M; Pham HP
J Med Econ; 2021; 24(1):1178-1184. PubMed ID: 34643472
[TBL] [Abstract][Full Text] [Related]
35. Caplacizumab: First Global Approval.
Duggan S
Drugs; 2018 Oct; 78(15):1639-1642. PubMed ID: 30298461
[TBL] [Abstract][Full Text] [Related]
36. Real-world data of the use and experience of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: Case series.
Albanell-Fernández M; Monge-Escartín I; Carcelero-San Martín E; Riu Viladoms G; Ruiz-Boy S; Lozano M; Soy D; Moreno-Castaño AB; Diaz-Ricart M; Cid J
Transfus Apher Sci; 2023 Jun; 62(3):103722. PubMed ID: 37169697
[TBL] [Abstract][Full Text] [Related]
37. Thrombotic Thrombocytopenic Purpura with Concomitant Progressive Cerebral Microbleeds.
Noorbakhsh-Sabet N; Zand R
J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):e214-e215. PubMed ID: 27693106
[TBL] [Abstract][Full Text] [Related]
38. Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study.
Arnaud A; Schilsky S; Lucia J; Maia M; Laredo F; Marques AP; Okada H; Roberts AW
Clin Appl Thromb Hemost; 2024; 30():10760296241241525. PubMed ID: 38523315
[TBL] [Abstract][Full Text] [Related]
39. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
Picod A; Veyradier A; Coppo P
J Thromb Haemost; 2021 Jan; 19(1):58-67. PubMed ID: 33236389
[TBL] [Abstract][Full Text] [Related]
40. Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program.
de Oliveira Boechat T; de Holanda Farias JS; Ribeiro EFO; de Andrade MLL
Ann Hematol; 2023 Jun; 102(6):1581-1588. PubMed ID: 37055582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
